AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00131690
Drug: Nescafé Gold Blend (exposed)
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00131690
Drug: Nescafé Decaffeinated (controls)
RxNorm normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02849509
Drug: Pradaxa (dabigatran)
RxNorm normalized name: Pradaxa
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pradaxa (dabigatran etexilate)110mg or 150mg
Trial: NCT05740371
Drug: Argatroban
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.~If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.~In cases ACT \> 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.~As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.~Depending on clinical relevancy further ACT assessments were possible.
Trial: NCT03074097
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
Trial: NCT02108483
Drug: dapsone gel
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patches containing dapsone gel will be applied to the skin.
Trial: NCT02108483
Drug: dapsone gel vehicle
RxNorm normalized name: dapsone Topical Gel
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patches containing dapsone gel vehicle will be applied to the skin.
Trial: NCT01922258
Drug: Brexpiprazole, OPC-34712
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
Trial: NCT00712894
Drug: Diltiazem
RxNorm normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary Infusion 400-2000ug
Trial: NCT00712894
Drug: Verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary Infusion 200-1000ug
Trial: NCT00712894
Drug: Nitroglycerin
RxNorm normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary Infusion 200-1000ug
Trial: NCT01005576
Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
Trial: NCT00784719
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
Trial: NCT00637026
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iressa
Trial: NCT00908414
Drug: TMC589354 BB mg
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
Trial: NCT00908414
Drug: TMC589354 DD mg
RxNorm normalized name: DDS
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
Trial: NCT00908414
Drug: TMC589354 YY mg
RxNorm normalized name: Peptide YY
DrugBank: Peptide YY (3-36) (DB05004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
Trial: NCT00908414
Drug: TMC310911 300 mg
DrugBank: TMC-310911 (DB15623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
Trial: NCT02849080
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration once-daily.
Trial: NCT02849080
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration once-daily.
Trial: NCT00598858
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00598858
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04374019
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin:~Days 1-2: Weight \< 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight \> 75kg: 5 tabs (15 mg total daily dose)
Trial: NCT04374019
Drug: Camostat Mesilate
RxNorm normalized name: Camostat mesilate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-14: 2 tab TID after a meal (600 mg total daily dose)
Trial: NCT04374019
Drug: Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Days 1-14:
Trial: NCT03899285
Drug: Citalopram 20mg or 40 mg (phase 2)
RxNorm normalized name: citalopram 20 MG
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.
Trial: NCT00523133
Drug: naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg naltrexone daily for 3 months
Trial: NCT00523133
Drug: naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg of naltrexone daily for 6 months
Trial: NCT00655668
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
Trial: NCT01948921
Drug: Meperidine
RxNorm normalized name: Meperidine
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03134729
Drug: Ropivacaine for Serratus Plane Block (SPB)
RxNorm normalized name: Fucus serratus extract
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serratus Plane Block (SPB) injection of low concentration Ropivacaine (30 ml, 0.3%), in the plane between the External Intercostal Muscle and the Serratus Anterior Muscle.
Trial: NCT01628783
Drug: escitalopram 10 mg
RxNorm normalized name: escitalopram 10 MG
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally once daily
Trial: NCT02040532
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
Trial: NCT03138356
Drug: 2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Used in Treatment B and Treatment E.
Trial: NCT03138356
Drug: 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Used in Treatment A and Treatment D.
Trial: NCT03138356
Drug: 5 mg dapagliflozin / 850 mg metformin XR FDC
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Used in Treatment H.
Trial: NCT03138356
Drug: 5 mg dapagliflozin / 1000 mg metformin XR FDC
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Used in Treatment G.
Trial: NCT02814279
Drug: Sodium dipyrone
RxNorm normalized name: dipyrone
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
Trial: NCT02814279
Drug: chlorhexidine rinse
RxNorm normalized name: chlorhexidine Mouthwash [Denti-Rinse]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
Trial: NCT02155985
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
Trial: NCT00672334
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
Trial: NCT02998151
Drug: Acamprosate
RxNorm normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two 666mg pills
Trial: NCT02998151
Drug: Baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one 30mg pill
Trial: NCT03734614
Drug: Low dose of aspirin
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose of aspirin, 100 mg daily for longer than one year
Trial: NCT02256813
Drug: BIRT 2584 XX
RxNorm normalized name: zinc gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02256813
Drug: Warfarin sodium
RxNorm normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02256813
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02256813
Drug: Dextromethorphan hydrobromide
RxNorm normalized name: Dextromethorphan Hydrobromide
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02256813
Drug: Midazolam hydrochloride
RxNorm normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02256813
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02070289
Drug: PF-06372865
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, 2.5 mg BID, 14 days
Trial: NCT02070289
Drug: PF-06372865
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, to be decided dose, BID or titration, 14 days
Trial: NCT00276016
Drug: phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: immediate-release 12 mg capsules for oral administration
Trial: NCT00276016
Drug: pseudoephedrine
RxNorm normalized name: Pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg immediate-release tablets for oral administration
Trial: NCT03653845
Drug: Sequenced antihypertensvie drugs with titrated dosage
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with different antihypertensive drugs in two groups.
Trial: NCT00005067
Drug: motexafin lutetium
RxNorm normalized name: Motexafin lutetium
DrugBank: Motexafin lutetium (DB05296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01889771
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nicoderm patches are distributed in two different supplies through a telephone quitline
Trial: NCT01690286
Drug: JNJ-38518168 3 mg
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral daily dose of JNJ-38518168 3 mg for 25 days.
Trial: NCT01690286
Drug: JNJ-38518168 30 mg
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral daily dose of JNJ-38518168 30 mg for 25 days.
Trial: NCT01690286
Drug: JNJ-38518168 10 mg
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral daily dose of JNJ-38518168 10 mg for 25 days.
Trial: NCT01690286
Drug: Ketoconazole 200 mg
RxNorm normalized name: ketoconazole 200 MG
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
Trial: NCT00563433
Drug: ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg twice a day for 14 days
Trial: NCT00563433
Drug: MSI-78
RxNorm normalized name: morphine sulfate Oral Solution [MSIR]
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1%/2% topical cream twice a day for 14 days
Trial: NCT02135419
Drug: imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Applied topically
Trial: NCT04143191
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.
Trial: NCT01388933
Drug: TU-100
RxNorm normalized name: TU-100
DrugBank: TU-100 (DB12467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15g daily, orally as 5g three times daily for 8 consecutive weeks
Trial: NCT02251821
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01843699
Drug: Topiramate flexible dosage
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01669720
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
Trial: NCT00990821
Drug: 100 MK-0517 (PS80) + 2 mg midazolam
RxNorm normalized name: midazolam 2 MG/ML
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
Trial: NCT00990821
Drug: 150 mg MK-0517 (Non-PS80)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
Trial: NCT00990821
Drug: 40 mg Aprepitant
RxNorm normalized name: aprepitant 40 MG
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant, oral, tablet, single dose
Trial: NCT00990821
Drug: 125 mg Aprepitant
RxNorm normalized name: aprepitant 125 MG
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant oral tablet, single dose
Trial: NCT00990821
Drug: 2 mg Midazolam
RxNorm normalized name: midazolam 2 MG/ML
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam oral tablet, single dose
Trial: NCT02251821
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02251821
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02251821
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT02251821
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02251821
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT01033097
Drug: Betamethasone 4 mg
RxNorm normalized name: betamethasone 4 MG/ML
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg oral
Trial: NCT01121497
Drug: Physostigmine
RxNorm normalized name: PHYSOSTIGMINE
DrugBank: Physostigmine (DB00981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
Trial: NCT04372186
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive one IV infusion of TCZ 8 mg/kg, with a maximum dose of 800 mg. Up to one additional dose may be given.
Trial: NCT01876823
Drug: es-citalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
Trial: NCT01876823
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
Trial: NCT03572998
Drug: Indocyanine Green (ICG)
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection of ICG as a fluorophore for Near Infrared fluorescence Imaging (NIRF)
Trial: NCT03379428
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
Trial: NCT03379428
Drug: Ibrutinib 560 mg
RxNorm normalized name: ibrutinib 560 MG
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 560 mg by mouth daily
Trial: NCT03379428
Drug: Ibrutinib 840 mg
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 840 mg by mouth daily
Trial: NCT03379428
Drug: Ibrutinib 420 mg
RxNorm normalized name: ibrutinib 420 MG
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 420 mg by mouth daily
Trial: NCT02648282
Drug: GVAX Pancreatic Cancer Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: GVAX (DB17276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of 8 doses. In the extended treatment phase, eligible patients may receive 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells administered one day after CY every 6 months for an additional 4 doses.
Trial: NCT02648282
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg as a 30 minute IV infusion every 21 days for an additional 9 doses.
Trial: NCT01503437
Drug: Olanzapine OD Tablets 5 mg
RxNorm normalized name: olanzapine Oral Tablet
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
Trial: NCT00711555
Drug: aprepitant, ondansetron, dexamethasone
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting.
Trial: NCT00674206
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m\^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal